The Emerging Role of GTF3C2-AS1 in Disease: A Promising Drug Target and Biomarker

Target Name: GTF3C2-AS1

NCBI ID: G100505624

GTF3C2-AS1

Other Name(s): GTF3C2 antisense RNA 1

The Emerging Role of GTF3C2-AS1 in Disease: A Promising Drug Target and Biomarker

Introduction

In recent years, researchers have been focusing on the identification of novel drug targets and biomarkers as a means of advancing precision medicine. One such potential candidate that has garnered considerable attention is GTF3C2-AS1. This article aims to explore the emerging role of GTF3C2-AS1 in disease, highlighting its potential as both a drug target and a biomarker.

Understanding GTF3C2-AS1

GTF3C2-AS1, also known as General Transcription Factor IIIC Subunit 2 Antisense RNA 1, is a long non-coding RNA (lncRNA) located on chromosome 17. LncRNAs are RNA molecules that have limited or no protein-coding capability but are involved in diverse cellular processes. GTF3C2-AS1, despite lacking protein-coding potential, has been found to have a significant impact on various biological processes.

GTF3C2-AS1 as a Drug Target

1. Oncogenesis

Research has unveiled a close association between GTF3C2-AS1 and oncogenesis, making it a compelling target for cancer therapies. Multiple studies have shown that GTF3C2-AS1 is upregulated in various cancer types, including lung cancer, breast cancer, and colorectal cancer. Its upregulation has been correlated with increased tumor growth, invasion, and metastasis.

Mechanistically, GTF3C2-AS1 has been implicated in the dysregulation of cellular processes such as cell cycle progression, apoptosis, and epithelial-mesenchymal transition (EMT). Targeting GTF3C2-AS1 using specific inhibitors or gene-editing techniques has demonstrated promising anti-cancer effects, inhibiting tumor growth and reducing metastasis in preclinical models.

2. Neurological Disorders

GTF3C2-AS1 has also been implicated in neurological disorders such as Alzheimer's disease and Parkinson's disease. Dysregulation of GTF3C2-AS1 has been observed in the brains of patients with these conditions, suggesting its involvement in disease pathogenesis.

Preclinical studies have begun exploring the therapeutic potential of targeting GTF3C2-AS1 in neurodegenerative diseases. By downregulating GTF3C2-AS1 expression, neuroinflammation and neurotoxicity can be attenuated, preserving neuronal health and improving cognitive function. Though in its early stages, this research suggests GTF3C2-AS1 as a potential therapeutic target worth investigating further.

GTF3C2-AS1 as a Biomarker

1. Diagnostic Biomarker

The differential expression of GTF3C2-AS1 in various diseases highlights its potential as a diagnostic biomarker. In bladder cancer, for example, GTF3C2-AS1 is significantly upregulated in tumor tissues compared to healthy controls. This upregulation makes it a promising non-invasive candidate for early detection and monitoring of bladder cancer.

Furthermore, GTF3C2-AS1 has shown diagnostic potential in other diseases such as non-small cell lung cancer and hepatocellular carcinoma. By quantifying the expression levels of GTF3C2-AS1, clinicians can potentially improve disease detection rates, aid in prognosis, and develop personalized treatment plans.

2. Prognostic Biomarker

In addition to its diagnostic utility, GTF3C2-AS1 has emerged as a prognostic biomarker in various cancers. Studies have revealed that higher expression levels of GTF3C2-AS1 are associated with worse overall survival rates and increased risk of disease recurrence.

For instance, in colorectal cancer, patients with high levels of GTF3C2-AS1 expression have shorter survival times compared to those with low expression. This correlation makes GTF3C2-AS1 a valuable prognostic marker, enabling clinicians to identify patients who require more aggressive treatments or frequent monitoring.

Conclusion

GTF3C2-AS1 is a fascinating molecule that exhibits significant potential as both a drug target and a biomarker. Through its involvement in oncogenesis and neurological disorders, it presents an opportunity for the development of novel therapies that can improve patient outcomes. Additionally, its differential expression patterns in various diseases make it an attractive candidate for diagnostic and prognostic applications. As research in this field progresses, further understanding of GTF3C2-AS1's precise mechanisms and therapeutic potential will undoubtedly fuel advancements in precision medicine.

Protein Name: GTF3C2 Antisense RNA 1

The "GTF3C2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF3C2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets